NS
SPRY icon

NBC Securities’s ARS Pharmaceuticals SPRY Stock Holding History

NBC Securities’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8 Hold
1
– – ﹤0.01% 2537
2025
Q4 		$11 Hold
1
– – ﹤0.01% 2773
2025
Q3 		$10 Buy
+1
New +$14 ﹤0.01% 2761

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

NBC Securities's SPRY Position: Q1 2026 in Review

NBC Securities held its ARS Pharmaceuticals (SPRY) position steady in Q1 2026 at 1 share worth $8. The position accounts for ﹤0.01% of the portfolio, ranked #2537.

NBC Securities first reported a position in SPRY in Q3 2025 and has held it in 3 quarters since. The position peaked at $11 in Q4 2025. 202 funds tracked by Wall St. Rank hold SPRY as of Q1 2026.

  • NBC Securities held 1 share of ARS Pharmaceuticals worth $8 as of Q1 2026.
  • NBC Securities left its ARS Pharmaceuticals share count unchanged in Q1 2026.
  • ARS Pharmaceuticals made up ﹤0.01% of NBC Securities's portfolio in Q1 2026, its #2537 holding.
  • NBC Securities first reported a position in ARS Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • NBC Securities's ARS Pharmaceuticals position peaked at $11 in Q4 2025.
  • 202 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2026.

Based on NBC Securities's 13F filing for Q1 2026, filed 14 Apr 2026.